Adaptimmune Therapeutics plc (ADAP)

NASDAQ: ADAP · IEX Real-Time Price · USD
1.280
+0.040 (3.23%)
At close: Jul 12, 2024, 4:00 PM
1.305
+0.025 (1.95%)
After-hours: Jul 12, 2024, 7:54 PM EDT
3.23%
Market Cap 327.03M
Revenue (ttm) 18.36M
Net Income (ttm) -163.41M
Shares Out 255.50M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,429,288
Open 1.220
Previous Close 1.240
Day's Range 1.219 - 1.340
52-Week Range 0.420 - 2.050
Beta 2.30
Analysts Buy
Price Target 4.29 (+235.16%)
Earnings Date Aug 7, 2024

About ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreemen... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 6, 2015
Employees 449
Stock Exchange NASDAQ
Ticker Symbol ADAP
Full Company Profile

Financial Performance

In 2023, ADAP's revenue was $60.28 million, an increase of 122.05% compared to the previous year's $27.15 million. Losses were -$113.87 million, -31.18% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ADAP stock is "Buy." The 12-month stock price forecast is $4.29, which is an increase of 235.16% from the latest price.

Price Target
$4.29
(235.16% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

We are initiating coverage of Adaptimmune Therapeutics plc ADAP with a 12-month price target of $3.00, translating into sizeable upside from the stock's current price. Adaptimmune designs, develops, m...

27 days ago - Benzinga

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the pote...

5 weeks ago - Newsfile Corp

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc...

Other symbols: GLPG
6 weeks ago - GlobeNewsWire

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized ma...

Other symbols: GLPG
6 weeks ago - Newsfile Corp

Adaptimmune Reports Q1 2024 Financial and Business Updates

Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing in...

2 months ago - Newsfile Corp

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval Philadelphia, Pennsylvania and Oxford, United Kindgom-...

Other symbols: HTGC
2 months ago - Newsfile Corp

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...

2 months ago - Newsfile Corp

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April...

3 months ago - Newsfile Corp

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with c...

3 months ago - Newsfile Corp

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024 Confirmatory evidence for afami-cel full approval agreed wi...

4 months ago - Newsfile Corp

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (...

4 months ago - Newsfile Corp

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers wit...

5 months ago - Newsfile Corp

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and O...

5 months ago - Newsfile Corp

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million BLA submitted in 2023 for afami-cel; projecte...

6 months ago - Newsfile Corp

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug Administration Afami-cel data demonstrate better outcomes for people with synovial sarcoma compared to histo...

7 months ago - Newsfile Corp

Adaptimmune Receives Transfer of IND for Lete-cel Program

Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma fr...

8 months ago - Newsfile Corp

Adaptimmune Reports Third Quarter Financial Results and Business Update

Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission on track to complete in Q4 this year SURPASS Phase 1 tr...

8 months ago - Newsfile Corp

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Candidate is 10x more sensitive to target peptide than competitor candidates Entry into the clinic in 2024 Selection of approaches from next-gen toolbox in development Philadelphia, Pennsylvania and O...

8 months ago - Newsfile Corp

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had clinical responses with lete-cel, by independent review[2]; primary efficacy endpoint requires...

9 months ago - Newsfile Corp

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response of ~12 months (CTOS 2022) Median overall survival (mOS) was ~17 month...

9 months ago - Newsfile Corp

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report fin...

9 months ago - Newsfile Corp

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26 patients...

9 months ago - Newsfile Corp

Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces th...

10 months ago - Newsfile Corp

Adaptimmune Reports Second Quarter Financial Results and Business Update

Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell potency assay - submission now targeted for Q4 2023 Tran...

1 year ago - Newsfile Corp

Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial ...

1 year ago - Newsfile Corp